Home | Links | FAQs | Contact | Feedback 
WELCOME

Aphase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intra-arterial (IA) approach to recanalization is superior to standard IV rt-PA (Activase®) alone when initiated within three hours of acute ischemic stroke onset.

IMPORTANT STUDY ANNOUNCEMENT:


The DSMB recommends that enrollment into the IMS-III study be put on hold, effective immediately. Subject follow-up should continue. The DSMB noted that there are no serious safety concerns. The study investigative team should remain blinded at this time. NINDS concurs with the IMS-III DSMB recommendations.

View the NINDS staement herehttp://www.ninds.nih.gov/disorders/clinical_trials/IMS-III.htm


 

What's New...

19 APRIL 2012:
IMPORTANT ANNOUNCEMENT:
The DSMB recommends that enrollment into the IMS-III study be put on hold, effective immediately. Subject follow-up should continue. The DSMB noted that there are no serious safety concerns. The study investigative team should remain blinded at this time. NINDS concurs with the IMS-III DSMB recommendations.
<<<Read More>>>

Learn More...

Acute Stroke Therapy at the Crossroads. . Broderick J, Meyers P. JAMA, 2011;306(18):2026-2028. doi: 10.1001/jama.2011.1622.
[View the article]